Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia

Ibrutinib is a covalently binding inhibitor of the B-cell receptor signaling-mediator Bruton’s tyrosine kinase (BTK) with great efficacy in chronic lymphocytic leukemia (CLL). Common side effects like atrial fibrillation (AF), bleeding and infections might be caused by ibrutinib’s inhibition of othe...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Hemasphere
Asıl Yazarlar: Mulder, Tom A., Peña-Pérez, Lucía, Berglöf, Anna, Meinke, Stephan, Estupiñán, H. Yesid, Heimersson, Kia, Zain, Rula, Månsson, Robert, Smith, C. I. Edvard, Palma, Marzia
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Lippincott Williams & Wilkins 2021
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078281/
https://ncbi.nlm.nih.gov/pubmed/33912812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/HS9.0000000000000564
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller